Key facts
- Elemental Biologics’s last known valuation is $27.0M (Apr 2026).
- It has raised $2.0M; the latest was Seed Round ($2.0M) in Apr 2026.
- Notable investors include Yazbeck & Co..
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Elemental Biologics
- ·The full record, as it builds
Funding rounds
No funding rounds for Elemental Biologics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Elemental Biologics
Developer of antibody therapeutics designed to treat inflammatory and other immune-driven diseases. The company offers antibody therapeutics targeting inflammatory and immune disease pathways for immune-driven diseases involving chronic inflammation and immune dysregulation, including autoimmune, inflammatory, and fibrotic diseases, as well as age-related inflammatory conditions with significant unmet medical need, enabling clients to address immune-driven conditions with more precise, biological treatments.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2023
- Employees
- 2
- Website
- elementalbiologics.com/
- Ownership
- Privately Held (backing)
Elemental Biologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elemental Biologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elemental Biologics in its N-PORT filings yet. We sweep new filings monthly.